BriaCell Therapeutics (TSE:BCT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BriaCell Therapeutics Corp., a clinical-stage biotech company focused on cancer immunotherapies, announced a $5 million at-the-market offering under Nasdaq rules. The offering includes over 5 million common shares and warrants, with the funds intended for working capital, corporate purposes, and advancing business objectives. The offering is expected to close on October 2, 2024, with ThinkEquity serving as the sole placement agent.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test
- “Direct Result of Your Feedback….” Microsoft Stock (NASDAQ:MSFT) Slips as The Option to Skip Updates Emerges